BioNTech's Oncology Ambition Fueled by New Lung Cancer Alliance and Governance Overhaul

BioNTech partners with Boehringer Ingelheim on a new lung cancer combo therapy and seeks shareholder approval for governance changes and capital increase to fund its oncology transformation.

BioNTech SE is accelerating its transformation into a dedicated oncology company, underscored by a new clinical collaboration and a series of shareholder votes designed to reshape its governance and financial structure. The Mainz-based biotech firm is pairing its strategic pipeline push with a clear operational pivot away from its pandemic-era footprint.

The company and Boehringer Ingelheim announced a partnership to develop a combination therapy for advanced small cell lung cancer. The planned Phase Ib/II trial will combine Boehringer’s experimental T-cell engager, obrixtamig, with BioNTech’s bispecific antibody candidate, pumitamig (BNT327/BMS-986545), which is being developed with Bristol Myers Squibb. Data has shown promise: in a Phase II study involving first-line patients, pumitamig demonstrated a confirmed objective response rate of 76.3% and a disease control rate of 100%, with a median progression-free survival of 6.8 months. Boehringer Ingelheim will hold the regulatory sponsorship for the study, with patient dosing scheduled to begin in the second half of 2026.

This alliance adds another layer to BioNTech’s expanding oncology portfolio, which currently includes 16 ongoing trials in lung cancer alone. Among these are four pivotal Phase 3 studies. Recent data presented at the European Lung Cancer Congress highlighted another candidate, gotistobart, an anti-CTLA-4 therapy that reduced the risk of death by 54% in second-line treatment for squamous non-small cell lung cancer.

Financing this ambitious clinical push requires significant capital, and BioNTech is asking shareholders to approve key measures at its virtual Annual General Meeting on May 15, 2026. The supervisory board is slated to expand from six to eight members, with a focus on oncology and clinical development expertise. The proposed new members are Dr. Susanne Schaffert and Prof. Dr. Iris Loew-Friedrich. Shareholders will also vote on creating new authorized capital of up to €129.5 million, equivalent to 50% of the current share capital.

The company’s financial strategy reflects the scale of its transition. The entire 2025 retained profit of approximately €6.9 billion will be carried forward, with no dividend planned. This move is linked to a domination and profit transfer agreement with subsidiary BioNTech Discovery GmbH, aimed at enabling tax loss offsets—a relevant consideration after BioNTech reported a net loss of €1.14 billion for the 2025 fiscal year.

Revenue projections starkly illustrate the post-pandemic shift. After peak COVID-19 vaccine sales of €17.3 billion in 2022, revenues fell to €2.87 billion in 2025. Guidance for 2026 anticipates total revenues between €2.0 and €2.3 billion, while research and development expenses are expected to climb to between €2.2 and €2.5 billion. This means the company is currently investing more in R&D than it generates in sales.

Operational restructuring continues to align with this new focus. BioNTech confirmed the closure of its Singapore manufacturing site, acquired from Novartis in 2022, with the wind-down of the 85-employee facility set for completion by the end of February 2027. This decision is part of a broader cost-saving program initiated in 2025 targeting $3 billion in savings.

Despite the near-term financial pressures, BioNTech maintains a substantial war chest to fund its multi-year transformation, with liquidity reserves of €17.2 billion. The company aims to grow its oncology pipeline to 15 ongoing Phase 3 trials by the end of 2026. While commercial revenue from these new cancer therapies is not expected in the current year, the stock market appears to be awaiting concrete regulatory milestones, with BioNTech shares trading roughly twelve percent below their 200-day moving average.